Participated · Equity · Nov 2023

Shanghai 陛通半导体能源科技股份有限公司 provides a broad set of technical services to domestic and international equipment manufacturers and end users, including equipment installation and commissioning, fault diagnosis and repair, equipment upgrades and relocations, full-plant moves, and process support. The company positions itself as a full-spectrum high-tech service provider for semiconductor equipment and related industrial facilities. It completed a new financing round totaling nearly RMB 500 million. Investors in the round include Juntong Capital, Jinpu Innovation, Shanghai Kechuang Group, Zhejiang Development Assets, SAIF Management, and Sanyuan Capital, with existing shareholders such as Lihe Capital and Changjiang Guohong participating. Following the financing, the company plans to increase investment in technology and product R&D, recruit additional talent, and introduce more domestically produced high-end thin-film deposition equipment models. It also intends to accelerate its industrialization and commercialization efforts.

Participated · Series A · Sep 2020

InxMed is a clinical-stage biotechnology company based in Nanjing that develops therapies targeting the stromal microenvironment to overcome solid tumor resistance and metastasis. Founded at the end of 2018 and led by CEO Dr. Zaiqi Wang, the company focuses particularly on addressing anti‑PD‑1/PD‑L1 treatment resistance. Its lead asset, IN10018, is a potent and highly selective ATP‑competitive FAK inhibitor for which InxMed holds exclusive global development and commercial rights. IN10018 received FDA fast track designation in August 2021 and a breakthrough designation from China’s NMPA for the treatment of platinum‑resistant ovarian cancer. InxMed plans to use the $15M raised in a Series B+ to accelerate ongoing clinical trials in the US and China, initiate pivotal trials in the second half year, advance additional stroma‑targeting programs into clinics, and strengthen R&D capabilities in Nanjing. The company has established partnerships with multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim and intends to disclose more IN10018 data at ASCO in June 2022. InxMed Co., Ltd is a clinical-stage biotechnology company based in Nanjing, China, focused on therapies that target the stromal microenvironment and drug resistance in hard-to-treat solid tumors. Its lead asset, IN10018, is a potent, selective ATP-competitive focal adhesion kinase (FAK) small-molecule inhibitor with ongoing trials in NRAS mutant metastatic melanoma, platinum-resistant ovarian cancer, and triple-negative breast cancer. The U.S. Food and Drug Administration granted Fast Track designation to IN10018 for platinum-resistant ovarian cancer in August 2021 based on preliminary efficacy. The company says it will use the $50M Series B proceeds to accelerate IN10018 clinical trials in both the U.S. and China, including initiation of pivotal trials, and to advance additional stroma-targeting programs into the clinic this year. InxMed has built translational medicine and clinical development teams across Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, and has partnerships with Merck, Roche, and Boehringer Ingelheim. The company is led by founder and CEO Dr. Zaiqi Wang and will strengthen R&D capabilities in Nanjing with the new funding. InxMed is a Nanjing-based biotech focused on developing FAK inhibitors. The company is advancing a program toward Phase I development of a FAK inhibitor. Nearly a year after securing its first IND approval, InxMed raised new capital to support clinical progress. The company completed a ¥130 million (about $19 million) Series A+ financing. Proceeds from the raise are intended to fund the Phase I FAK inhibitor program. Zaiqi Wang is named as CEO.